NewsBenzingaKodiak Sciences Says Phase 3 DAYBREAK Study Met Primary Endpoints With Zenkuda (Tarcocimab Tedromer) And Tabirafusp-ted (KSI-501) Showing Non-inferiority In Vision Gains For Wet Age-related Macular Degeneration Vs. Aflibercept At Year One Kodiak Sciences Says Phase 3 DAYBREAK Study Met Primary Endpoints With Zenkuda (Tarcocimab Tedromer) And Tabirafusp-ted (KSI-501) Showing Non-inferiority In Vision Gains For Wet Age-related Macular Degeneration Vs. Aflibercept At Year One Benzinga 2026.09.28 10:34 (GMT+0) Open on Benzinga Other news This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Morgan Stanley Maintains Underweight on Bank OZK, Raises Price Target to $57 Ondas’ Subsidiary Cyberhawk Secures New 3-Yr Agreement, With Option To Extend For Further Two Years, With SSE Plc's Economically-Regulated Networks Businesses For Provision Of Specialist Drone Inspection And Surveying Services Sidus Space Announces That LizzieSat-4 And LizzieSat-5 Are Currently Aligned With Launch On The SpaceX Bandwagon-6 Rideshare Mission, Targeted For No Earlier Than April 2027 Moving iMage Technologies Q4 EPS $(0.03) Down From $(0.02) YoY, Sales $4.545M Down From $5.883M YoY Morgan Stanley Maintains Equal-Weight on Atlantic Union Bankshares, Raises Price Target to $50
This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Ondas’ Subsidiary Cyberhawk Secures New 3-Yr Agreement, With Option To Extend For Further Two Years, With SSE Plc's Economically-Regulated Networks Businesses For Provision Of Specialist Drone Inspection And Surveying Services
Sidus Space Announces That LizzieSat-4 And LizzieSat-5 Are Currently Aligned With Launch On The SpaceX Bandwagon-6 Rideshare Mission, Targeted For No Earlier Than April 2027
